News

Aviva Invests in Owlstone Medical Breath Biopsy® platform

Owlstone Medical announce an investment from Aviva Ventures, the venture capital arm of Aviva plc, a global leader in insurance. The investment takes Owlstone Medical’s total funding to $23.5 million USD (£19.3 million GBP) since its spin-out from Owlstone Inc in 2016 and will be used to drive test adoption and commercialization of the company’s Breath Biopsy® platform.

Owlstone Medical CEO and Breath Biopsy Pioneer Billy Boyle wins Royal Academy of Engineering’s Silver Medal

ASMS 2017 ultraFAIMS posters

How is ion mobility being used?

Who is publishing in the ion mobility field?

Owlstone Medical Establishes Scientific Advisory Board with Appointment of Professor Sir Bruce Ponder

LuCID Nurses visit Owlstone Medical HQ

Owlstone Medical advancing against cancer

One Day, a Machine Will Smell Whether You’re Sick - The New York Times

Take a breath – this could be the definitive cancer screening tool

An introduction to combining Ion Mobility with Mass Spectrometry

Retrofit ultraFAIMS in 3 simple steps

Owlstone Medical and Mayo Clinic Collaborate to Develop Pre-Endoscopic Test to Improve Effectiveness of Colonoscopy